Shares of biotech company Regeneron (NASDAQ:REGN)
fell 4.1% in the afternoon session after the company highlighted challenges, including regulatory approvals and competitive pressures, at a healthcare forum.
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Shares of biotech company Regeneron (NASDAQ:REGN)
fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its blockbuster eye drug, EYLEA.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Regeneron Pharmaceuticals (REGN) is a top value stock with a low P/E ratio, strong profitability, and excellent financial health, offering a potential margin of safety for investors.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's consistent downward trend has historically preceded recessions, The Conference Board maintains a nuanced outlook, forecasting a "significant slowdown" rather
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products, and even the cost of staying healthy, prices are already on an upward trajectory or are poised for substantial hikes.
The global economy is currently grappling with a projected deceleration in GDP growth, a situation severely exacerbated by an unprecedented escalation of U.S. tariffs. These twin forces are creating a potent cocktail of stagflationary pressures, threatening to disrupt corporate supply chains, erode investor confidence, and reshape the landscape of
Regeneron's Phase 3 trials for cat and birch allergies show significant symptom relief and strong safety results, paving the way for future development.
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.
